AER 1632718 is a spontaneous case, received on 10/Sep/2015 from a physician via Paul-Ehrlich Institute 
(Germany) and it concerns a 68 year old female patient (manufacturing control number:DEPEIPEI2015054603) 
who developed progressive multifocal leukoencephalopathy, progressive hemiparesis, acute neurological 
symptoms whilst being treated with rituximab (Mabthera).
Medical history included thrombosis (V. portage, V. mesenterica superior) /Jan/2010, renal vein thrombosis left 
/Feb/2008, symmetrical leg accented polyneuropathy /Jan/2008-//2010), nicotine abusus (30 py) /Jan/2008. 
Concomitant medications included bendamustine, methotrexate and ifosfamide. No past drugs and concurrent 
conditions were reported.
On an unknown date in /Nov/2007, the patient started therapy with intravenous (IV) rituximab (375 mg/m2) for 
marginal zone lymphoma. In Apr/2008, rituximab was stopped.  On an unknown date in /May/2015, she restarted 
therapy with intravenous rituximab (375 mg/m2). On (b) (6)  after administration of rituximab, she developed 
hemiparesis left and progressive multifocal leukoencephalopathy and neurological symptoms lasting for unknown 
duration. She was hospitalized and condition was life threatening. On same day, diagnosis was confirmed by 
nuclear magnetic resonance angiography brain. On (b) (6)  cerebrospinal fluid test showed JC virus (John 
Cunningham virus) positive.  On an unspecified date/Jul/2015, therapy with rituximab was discontinued. Symptoms 
were improving but she was not completely recovered at the date of reporting. 
The physician did not report a causality between progressive multifocal leukoencephalopathy, progressive 
hemiparesis and acute neurological symptoms with rituximab.
No further information was reported.
This confirmed case of progressive multifocal leukoencephalopathy (PML) is being expedited per 
Roche/Genentech Enhanced Pharmacovigilance Plan for PML